European Leukemia Trial Registry
Trial: CA180-373

More Details
Title Phase I Study with Dasatinib plus Nivolumab in CML
Scientific Title A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination of Dasatinib (BMS-354825) plus Nivolumab (BMS-936558) in Patients with Chronic Myeloid Leukemia (CML)
Short Title CA180-373
Trialgroup CML-Studiengruppe
Type of Trial multicentric, single-group, prospective, open-label
Disease Chronic myeloid leukemia(CML) Accelerated phase
Chronic myeloid leukemia(CML) Chronic Phase
Age >= 18 years
Status No longer recruiting
Start of Recruitment 01.04.2014
Leader Ottmann, Prof. Dr., Oliver
Contactperson

Administrative needs
Binckebanck, Anja
Tel: +49 (0)69 6301-6221
Fax: +49 (0)69 6301-7463
Email: binckebanck@em.uni-frankfurt.de

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
created 28.08.2014 Johannes Kraus
changed 14.11.2016 Eva-Maria Ableidinger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org